10 Questions For Teva's BD Chief
This article was originally published in Scrip
Executive Summary
Since joining Teva Pharmaceutical Co. Ltd. in 2013, Dr. Ivana Magovcevic-Liebisch, senior vice president and head of global business development, has been tasked with bringing innovation into the firm and leading partnerships and collaborations for the company's specialty pharma unit.
You may also be interested in...
'No Meaningful Change' In Pricing Environment, Teva Says
Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.